Background {#Sec1}
==========

Breast cancer (BC) is comprised of several molecular subtypes with varied biological and clinical characteristics. Of these, the four most discernible subtypes by gene expression profiling include the two estrogen-receptor (ER)-positive subtypes, luminal A and B which are characterized by low and high proliferation, respectively; the HER2 subtype characterized by overexpression of genes in the HER2 (*ERBB2*) amplicon; and the basal-like BC (BLBC) subtype characterized by expression of basally-oriented mammary epithelial cell markers such as cytokeratins 5 and 14 (CK5/14), lack of hormone receptors and HER2 expression ("triple-negative"), and high genomic instability \[[@CR1]\]. Although therapies that target estrogen pathways or the HER2 receptor are part of the standard armamentarium in clinical use today, currently no specific drugs that target the basal-like subtype are approved. The basal-like subtype also has a particularly poor prognosis, underscoring the need for improved therapeutic options for women with this class of cancer.

Recent studies point to the importance of the phosphatidylinositol 3-kinase (PI3K) and phosphatase and tensin homolog deleted on chromosome ten (PTEN) oncogene/tumor suppressor axis in breast tumorigenesis. The *PIK3CA* oncogene, which encodes the PI3K p110 catalytic subunit alpha and phosphorylates phosphatidylinositol 3,4-bisphosphate (PIP2) to PIP3, has been shown to have activating mutations in approximately 30 % of BCs, primarily within ER-positive cases \[[@CR2]--[@CR6]\]. Although the tumor suppressor PTEN, a lipid phosphatase acting in direct enzymatic opposition to PI3K, is infrequently inactivated by mutations in sporadic BC (5 %), PTEN protein expression is significantly reduced in \~25 % breast tumors, more commonly in ER-negative cancer and in particular within BLBC, and rarely coinciding with *PIK3CA* mutation \[[@CR2], [@CR7]\]. *PTEN* is also frequently grossly mutated in *BRCA1*-hereditary BC, a group of tumors that usually exhibit the basal-like phenotype \[[@CR7], [@CR8]\], and new nuclear roles for PTEN in maintaining genome stability have been identified. Another lipid phosphatase, inositol polyphosphate 4-phosphatase type II (INPP4B), has recently been shown to have potential tumor suppressor activity \[[@CR9], [@CR10]\]. The tumor suppressive role of INPP4B is linked to its function in dephosphorylating PIP2, depleting this substrate of PI3K, and accordingly loss of INPP4B leads to increased PIP3-mediated signaling to AKT and is associated with poor outcome (reviewed in \[[@CR11]\]). Additionally, numerous upstream receptor tyrosine kinases (RTKs), such as HER2 and EGFR, have been shown to activate PI3K pathway signaling \[[@CR12], [@CR13]\], and EGFR also potently signals through the RAS/RAF/MEK (MAPK) pathway \[[@CR14]\]. Constitutive activation of PI3K pathway by *PTEN* mutation/loss or *PIK3CA* mutation could render tumor cells independent of RTKs for malignant transformation and maintenance, which leads to resistance to HER2-targeted therapies in BC and EGFR-targeted therapies in glioma \[[@CR15]--[@CR20]\].

To understand the natural history of PI3K pathway activating alterations and relate them to BC subtypes and other molecular and genetic alterations, we have performed an extensive analysis of pathway biomarker lesions in an unselected cohort of breast tumors. We examined the incidence of pathway lesions, and discovered novel associations to standard clinicopathological markers and to BC subtypes including the frequent coincident loss of PTEN and overexpression of EGFR in BLBC. We then assessed whether a combination therapeutic strategy targeting both the PTEN/PI3K pathway and EGFR would be more effective than monotherapy using in vitro and in vivo models.

Methods {#Sec2}
=======

Human breast cancer samples {#Sec3}
---------------------------

For 116 primary BC patients consented and treated at Columbia University Herbert Irving Comprehensive Cancer Center/New York-Presbyterian Hospital, formalin-fixed paraffin-embedded (FFPE) tumor blocks and DNA and total RNA isolated from corresponding frozen tumor specimens were obtained (Columbia cohort; Table [1](#Tab1){ref-type="table"}). All samples were blinded and anonymized and obtained with ethics approval from Columbia University's Institutional Review Board. This unselected cohort is comprised of patients diagnosed between 1986 and 2003 with all stages of BC and the patients received standard of care therapies. FFPE tissue microarrays for an independent series of 295 consecutive women with stage I and II breast cancer treated at the Netherlands Cancer Institute (NKI) was obtained \[[@CR21], [@CR22]\].Table 1PTEN/PI3K biomarkers in 116 unselected breast cancersVariable*n*%TotalBreast tumors116100.0 %116Median age (range)53 years(30--89)ER+8270.7 %116ER--3429.3 %PgR+7161.2 %116PgR--4538.8 %Size \<203631.3 %11520--496455.7 %50+1513.0 %Grade 187.0 %115Grade 23227.8 %Grade 37565.2 %Node+5653.3 %105Node--4946.7 %HER2+2320.4 %113HER2--9079.6 %Ki67 IHC+3538.0 %92Ki67 IHC--5762.0 %S--phase ≤6 %3133.3 %93S--phase \>6 %,\<10 %1718.3 %S--phase ≥10 %4548.4 %CK5/14 IHC+1917.4 %109CK5/14 IHC--9082.6 %p53 mut4438.3 %115p53 wt7161.7 %EGFR IHC+2724.1 %112EGFR IHC--8575.9 %PTEN abrogated (PTEN IHC- or mut)2624.3 %107PTEN norm8175.7 %PTEN IHC--2523.4 %107PTEN IHC+8276.6 %PTEN mut43.6 %112PTEN wt10896.4 %PIK3CA mut2925.0 %116PIK3CA wt8775.0 %INPP4B mRNA low2021.3 %94INPP4B mRNA norm7478.7 %Any PTEN/PI3K/INPP4B6464.0 %100None PTEN/PI3K/INPP4B3636.0 %Any PTEN/PI3K/INPP4B/EGFR/HER28075.5 %106None PTEN/PI3K/INPP4B/EGFR/HER22624.5 %

Tissue microarray construction {#Sec4}
------------------------------

Tissue microarrays (TMAs) were constructed for the Columbia cohort by the Experimental Molecular Pathology Core Facility of the Herbert Irving Comprehensive Cancer Center utilizing a Manual Tissue Arrayer-1 device (Beecher Instruments, Sun Prairie, WI). Tumor and normal tissue areas were identified using hematoxylin and eosin-stained sections, with 3 representative tumor and 3 representative normal tissue cores of 1-mm diameter taken from each FFPE case and inserted into the recipient blocks.

Immunohistochemistry and Western blotting {#Sec5}
-----------------------------------------

The Columbia cohort were analyzed by immunohistochemistry (IHC) for expression of the following proteins: PTEN, EGFR, cytokeratins 5 and 14 (CK5/14), stathmin, and Ki67. The NKI series TMAs were analyzed herein for CK5/14 and stathmin by IHC and previously immunostained for PTEN protein \[[@CR23]\]. PTEN IHC was performed on 4-μm FFPE whole-mount tissue sections using the monoclonal 138G6 PTEN antibody (Cell Signaling, Danvers, MA) at 1:200 dilution for 2 h at room temperature. Microwave antigen retrieval was accomplished using the Dako pH 9 solution for 20 min, followed by automated staining using the DakoCytomation TechMate 500 staining system with manufacturer's recommended reagents and Dako EnVision + signal detection (Dako, Carpinteria, CA). PTEN staining intensity scores for invasive tumor and non-neoplastic cells was evaluated and the tumors classified as PTEN-negative (PTEN^−^) and PTEN-positive (PTEN^+^) as described previously \[[@CR2]\]. Normal epithelial and endothelial cell staining were used as internal positive controls. EGFR IHC was performed using antibody 31G7 (Zymed/Invitrogen, South San Francisco, CA) at 375 ng/ml (1:40) on 4-μm TMA sections. Slides were treated for 5 min with Dako proteinase K and washed prior to incubating in primary antibody for 45 min at room temperature. Anti-mouse secondary antibody was applied for 30 min, and the signal detected using diaminobenzidine (DAB) chromogen for 3 min followed by DAB Enhancer for 4 min (all Dako). The slides were counterstained with Gils Hematoxylin. EGFR staining was evaluated using a threshold of ≤10 % positive tumor cells as EGFR-negative (EGFR^−^) and \>10 % positive tumor cells as EGFR-positive (EGFR^+^). CK5/14 IHC was performed on TMAs using an antibody cocktail and the cases scored CK5/14-positive (CK5/14^+^) or CK5/14-negative (CK5/14^−^) as described previously \[[@CR24]\]. Stathmin IHC was performed on TMAs and evaluated as previously described \[[@CR25]\]. Ki67 mouse monoclonal antibody Ki-S5 (Dako) was used at 1:50 on whole-mount tissue sections. IHC was performed on a Dako autostainer, using a Vector biotinylated secondary anti-mouse antibody (1:200 for 30 min) and Vectastain Elite detection with DAB (Vector Laboratories, Burlingame, CA). Sections were counterstained with methyl green (Sigma, St. Louis, MO). Appropriate positive and negative (staining lacking primary antibodies) controls were used in each batch of staining. Evaluation of Ki67 was performed by determining the percentage of positive tumor nuclei as evaluated by the CASS 200 Image Analyzer (Becton Dickinson, San Jose, CA). Cases were considered Ki67-positive when ≥20 % of the tumor cells showed evidence of nuclear expression. For Western blotting, the following antibodies were used: pEGFR (Tyr1068; \#3777), pAKT (Ser473; \#9271), AKT (\#9272) (all Cell Signaling), EGFR (Santa Cruz Biotechnology, Santa Cruz, CA; sc-03), and β-actin (Sigma-Aldrich, St. Louis, MO; AC-74 \#A5316).

HER2 amplification {#Sec6}
------------------

*HER2* amplification was assessed for 101 Columbia cases using chromogenic in situ hybridization (CISH) on TMAs, with six or more signals per cell in \>50 % of cancer cells scored as *HER2*-amplified (HER2^+^) \[[@CR26]\]. Tumors in which the majority of cells contained 5 or fewer signals per nucleus were scored *HER2*-non-amplified (HER2^−^). HER2 scores by IHC were used for 6 additional cases for which CISH hybridization failed; HER2 IHC methods are described in \[[@CR2]\]. The clinical diagnostic pathology evaluation for HER2 was utilized for another 6 cases lacking *HER2* CISH and IHC data.

PCR and sequence analysis {#Sec7}
-------------------------

Sequencing of *PIK3CA* exons 1, 2, 4, 5, 7, 9, 12, 13, 18, and 20 for the Columbia cohort of cases has been described previously \[[@CR2]\]. In the present study we have performed additional mutational analysis of the Columbia cohort for *PTEN* and *TP53*. Mutational screening of *TP53* exons 2 through 11 was performed using 8 pre-validated primer assays and direct bi-directional sequencing (Agencourt Bioscience, Beverly, MA). *PTEN* and *TP53* sequence traces were analyzed using Mutation Surveyor (Softgenetics, State College, PA) and Polyphred (<http://droog.gs.washington.edu/polyphred/>), respectively.

Gene expression profiling {#Sec8}
-------------------------

Gene expression profiles were generated for 95 Columiba cases using Agilent 44 K microarrays following the manufacturer protocol and scanned on an Agilent Microarray Scanner. Stratagene Universal Human Reference RNA was used as the common control sample. Images were analyzed using the Agilent Feature Extraction Software and the raw data loaded into BASE \[[@CR27]\] for processing. Background-corrected intensities (mean foreground -- median background) were filtered for values with A \> 0.5 (A = log~10~(channel1 \* channel2)/2) and the data normalized using the Lowess algorithm. Tumors were dichotomized into *INPP4* low and high categories, with low defined as the log2 ratio \<0 (20 cases) in expression as measured by the microarray *INPP4* probe A_24_P915492. The tumors were classified into the Hu et al. \[[@CR28]\] intrinsic molecular subtypes (luminal A, luminal B, HER2, basal-like, or normal-like): 301 unique gene symbols from Hu et al. mapped to 273 gene symbols in our data. The log2 data were averaged on gene symbol and centered across all samples, and classified into subtypes based on the best Pearson correlation to the Hu centroids. The tumors were classified by the PTEN-loss signature \[[@CR25]\]: 173 unique gene symbols from Saal et al. mapped to 143 gene symbols in the 44 K microarray data. The data were similarly averaged and centered as above, and the PTEN-loss-signature present or absent score calculated as described previously with a sample \|score\| \<0.2 set as unclassified \[[@CR25]\]. Microarray data are available from the NCBI Gene Expression Omnibus (<http://www.ncbi.nlm.nih.gov/geo/>) under accession GSE74667. Previously published microarray data and molecular subtyping was retrieved for the NKI series \[[@CR21], [@CR22]\].

Cell viability and apoptosis assays {#Sec9}
-----------------------------------

Cells were seeded in 96-well plates at a density of 5,000-8,000 cells in triplicates. After 24 h, cells were treated with different concentrations of the indicated inhibitors and incubated at 37 °C. The cells were cultured for 4 days and then the number of viable cells was measured by CellTiter-Glo luminescent cell viability assay according to the manufacturer's standard protocol (Promega). Analysis for synergistic drug combination efficacy was carried out using the method of Chou and Talalay \[[@CR29]\] using CompuSyn 3.0.1 (ComboSyn Inc., Paramus, NJ). Combination index (CI) values of \<1 are taken to indicate synergistic interaction between drugs, and CI values of \>1 indicate drug antagonism. To measure apoptosis, both adherent and floating cells were harvested after drug treatment, and the cell nuclei were stained with ethidium bromide \[[@CR30]\]. Detection and quantitation of apoptotic cells (sub-G1 fraction) were performed by flow cytometric analysis as described previously \[[@CR18]\].

Animal studies {#Sec10}
--------------

Six-week-old *nu/nu* athymic female mice (NCI-Frederick Cancer Center, Frederick, MD) were maintained in pressurized ventilated cages. Experiments were carried out under an IACUC approved protocol and institutional guidelines for the proper and humane use of animals in research were followed. MDA-MB-468 xenograft tumors were generated by transplanting 1.0--1.5 × 10^7^ MDA-468 cells in a 1:1 mixture of media and Matrigel (BD Biosciences, San Jose, CA) into the right flank (200 μl/mouse). After 7--10 days, the mice bearing tumors 6--7 mm in diameter were randomized among control and the various treated groups (5 mice/group). Gefitinib prepared as a lactate salt (pH 5.2) was administrated orally at a dose of 150 mg/kg/day × 5 consecutive days each week for 3 weeks. PWT-458 was freshly prepared in PBS, and administrated by intravenous injection at a dose of 100 mg/kg/day × 5 consecutive days each week for 3 weeks. For the combination treatment, PWT-458 was administrated 3--4 h before gefitinib treatment. The average tumor diameter (two perpendicular axes of the tumor were measured) was measured in control and treated groups using a caliper. The data are expressed as the increase or decrease in tumor volume in mm^3^ (volume = π/6 × \[larger diameter\] × \[smaller diameter\]^2^). For Western blot experiments, animals with established tumors were sacrificed 5 h after treatment and tumor lysates were prepared in 2 % SDS buffer as described previously \[[@CR18]\].

Data visualization and statistical analysis {#Sec11}
-------------------------------------------

Hierarchical clustering of marker data and tumors were performed in Cluster 3.0 \[[@CR31]\] utilizing the Pearson correlation distance metric (centered) and complete linkage algorithm and the data visualized using Java Treeview \[[@CR32]\]. The Pearson χ^2^ test was used for correlation analyses between two binary variables or between variables with more than 2 unordered groups, and the χ^2^ test for trend was used for analyses between variables with more than 2 ordered groups. Calculations were performed using R version 3.1.0. All tests were two-sided and a *P*-value \< 0.05 was used as the cut-off for decisions of statistical significance.

Results {#Sec12}
=======

Distribution of biomarker lesions {#Sec13}
---------------------------------

Our unselected Columbia cohort of 116 BCs is representative of the population seen at the Herbert Irving Comprehensive Cancer Center (Table [1](#Tab1){ref-type="table"}). The median age at diagnosis was 53 (range 30 to 89), 71 % of cases were ER-positive, 61 % progesterone receptor (PgR) positive, 31 % were \<2-cm and 87 % were \<5-cm. The majority of cases were of higher grade, approximately half had S-phase fraction \>10 %, and 53 % had lymph node-positive disease at diagnosis. Biomarker status was determined for PTEN (mutations and immunohistochemistry \[IHC\]), *PIK3CA* (mutations), *HER2* (amplification), EGFR (IHC), *INPP4B* (mRNA expression), CK5/14 (IHC), and *TP53* (mutations). Thirty-eight % of cases had deleterious mutations of *TP53*, in line with the expected *TP53* mutation rate in BC \[[@CR33]\]. Seventeen % were positive for the basal cytokeratins CK5/14 (which herein we use to define immunohistochemical BLBC; IHC-BLBC), consistent with reported rates \[[@CR34]\]. As shown in Table [1](#Tab1){ref-type="table"}, alteration of pathway members PTEN (24 %), *PIK3CA* (25 %), *HER2* (20 %), EGFR (24 %), and *INPP4B* (21 %) was common and the rates were in accordance with the literature \[[@CR2], [@CR35]--[@CR40]\]. When these five markers were combined into a 'pathway hit' variable (positive if any of the 5 markers were altered), 75 % of breast tumors harbored one or more alterations that contribute to PTEN/PI3K pathway activation.

PTEN/PI3K pathway-related tumor clusters {#Sec14}
----------------------------------------

To visualize these biomarker data we utilized unsupervised hierarchical clustering. As shown in Fig. [1a](#Fig1){ref-type="fig"}, the 116 tumors were clustered into four clusters by virtue of the intrinsic relationships between the markers ER, PgR, PTEN, *PIK3CA*, *HER2*, EGFR, *INPP4B*, CK5/14, and *TP53*. Cluster A, containing 22 tumors, is largely defined by lack of ER and/or PgR hormone receptor expression (15/22; 68 % expressed neither receptor and no case co-expressed both receptors), EGFR-overexpression (18/22; 82 %), IHC-BLBC status (15/22; 68 %), mutated *TP53* (18/22; 82 %), and PTEN-loss (14/21; 67 %). When annotated to additional clinicopathological data not utilized in generating the clusters (Fig. [1b](#Fig1){ref-type="fig"}), we note that this cluster contained entirely histological grade 3 tumors (22/22; 100 %) and had the highest proportion of Ki67-positive tumors (13/17; 76 %). Ten tumors formed cluster B, which is characterized primarily by lack of hormone receptor expression (0 %), *HER2*-amplification (80 %), and high histological grade (70 %). A large group of 67 tumors form cluster C, which are characterized by being predominantly ER-postive and PgR-postive (65/67; 97 %). Cluster C subclusters are defined by loss of *INPP4B* (subcluster C1), general lack of any other aberrations (C2), *PIK3CA* mutation-positive without *TP53* mutation (C3) or with *TP53* mutation (C5), and *HER2*-amplified cases with *TP53* mutation (C4). Cluster D is defined by ER-postive/PgR-negative without other aberrations (Fig. [1a](#Fig1){ref-type="fig"}).Fig. 1Clustering of unselected breast tumors. **a** The biomarker variables ER, PgR, PIK3CA, TP53, HER2, PTEN, EGFR, and CK5/14 were used to hierarchically cluster 116 breast tumors. Biomarker data are colored such that red = positive, black = negative, green = mutant (TP53) or lost (INPP4B, PTEN; asterix denotes PTEN mutation), and grey = missing data. **b** Below the heatmap are additional clinicopathological annotations not used to generate the clustered heatmap: Ki67, S-phase fraction (SPF), histological grade, PTEN-loss signature status, and intrinsic molecular subtype by gene expression profilling. For each annotation, color key is shown to the right (grey = missing data). SP = signature present; SA = signature absent; NC = not classified

Microarray gene expression profiling (GEX) was performed to further discern biological insight into the biomarker-defined clusters. Cluster A tumors were predominantly classified as belonging to the basal-like intrinsic molecular subtype (termed GEX-BLBC herein) (16/18; 89 %), and 75 % of the tumors (15/18) were classified, using our previously described signature, as having a gene expression pattern of PTEN-loss (Fig. [1b](#Fig1){ref-type="fig"}). In line with expectations, 50 % of cluster B belonged to the HER2-enriched subtype by GEX, and 50 % of cluster B expressed the PTEN-loss-like signature. Clusters C and D were primarily luminal subtype by GEX (75 %: 51 % luminal A, 24 % luminal B) and only 29 % had an expression profile of PTEN-loss. Subcluster C4 (HER2-amplified) was predominantly HER2-enriched or luminal B subtype (75 %). As previously described \[[@CR41], [@CR42]\], the subgroups for BLBC status defined by GEX, CK5/14, or triple-negative receptors were not completely synonymous (Fig. [1](#Fig1){ref-type="fig"}). Finally, across the dataset the PTEN IHC-negative cases were predominantly classified as having the expression signature of PTEN-loss (*P* = 0.019).

The differences in the distribution of Ki67 status, tumor grade, intrinsic molecular subtypes, and presence of the PTEN-loss signature across the main tumor clusters A-D were significant (*P* = 0.0009, *P* = 0.0067, *P* \< 0.0001, *P* = 0.0012, respectively). However, the distribution of lymph node status and S-phase fraction were not related to the biomarker clusters (*P* = 0.2947 and *P* = 0.2604, respectively) (Fig. [1b](#Fig1){ref-type="fig"}). We performed IHC for stathmin, a PTEN signature gene that we have previously shown to be upregulated in breast tumors with PI3K/PTEN pathway activation \[[@CR25]\]. Confirming our previous findings, stathmin protein levels were significantly higher in tumors with PTEN protein loss (*P* = 0.0015), with PTEN abrogation (*P* = 0.0015), and in tumors expressing the PTEN-loss gene expression signature (*P* = 0.0005) (Fig. [1b](#Fig1){ref-type="fig"}).

Associations between pathway lesions {#Sec15}
------------------------------------

We next wanted to evaluate the relationship of PTEN/PI3K/INPP4B/RTK pathway lesions to each other. We have previously reported in a series of Swedish stage II sporadic breast carcinomas that mutations of *PIK3CA* and loss of PTEN are mutually exclusive \[[@CR2]\]. Confirming this in our independent unselected patient cohort, *PIK3CA* and PTEN loss were essentially mutually exclusive with only one tumor being both *PIK3CA* mutated and PTEN IHC-negative (*P* = 0.0116; Table [2](#Tab2){ref-type="table"}). When including *PTEN* mutational data only two cases had mutant *PIK3CA* and abrogated PTEN (either PTEN IHC-negative or PTEN-mutant) (*P* = 0.0718). Together, this implies that there is little selective pressure to activate the pathway by hitting both enzymes at the PIP~3~ axis in breast tumors. Interestingly, the single case mutated for both *PTEN* and *PIK3CA* was PTEN IHC-positive and harbored a *PTEN* I28T mutation together with the *PIK3CA* E545K mutation. *PTEN* I28T mutation, to our knowledge, has not been reported in the literature in any tumor type and mutation at residue 28 has been reported in only three times (COSMIC Database, <http://www.sanger.ac.uk/genetics/CGP/cosmic/>). Given that this *PTEN* mutant was the only mutant (out of 4) that was PTEN IHC-positive, the functional relevance of this mutation is not clear. Intriguingly, more than half of the cases with loss or abrogation of PTEN protein expression overexpressed EGFR (*P* \< 0.0001 and *P* \< 0.0001, respectively), suggesting cooperation between EGFR and PTEN/PI3K signaling. Similarly, tumors with EGFR overexpression frequently had low *INPP4B* expression (*P* = 0.0189). No other significant associations were noted between PTEN/PI3K pathway alterations (Table [2](#Tab2){ref-type="table"}).Table 2Associations between pathway alterationsPTEN mutPTEN wtnpHER2+HER2-npEGFR+EGFR-npPIK3CA mutPIK3CA wtnpINPP4B lowINPP4B highnpPTEN IHC-320103**0.010**2231070.1171411107**\<0.0001**124107**0.012**611850.111PTEN IHC+1791864127023591256PTEN abrogation2241070.0981412107**\<0.0001**2241070.072612850.155PTEN normal1863126922591255HER2+8141100.1506171130.871315910.624HER2-196922681657EGFR+5221120.43681290**0.019**EGFR-22631159PIK3CA mut424940.281PIK3CA wt1650Footnote: Significant *p-*values are indicated by boldingAbbreviations: *mut* mutant, *wt* wild-type

Pathway lesions and clinicopathological variables {#Sec16}
-------------------------------------------------

Given the inherent biological groups identified by unsupervised hierarchical clustering analysis (Fig. [1](#Fig1){ref-type="fig"}), we queried the correlation of pathway lesions to common clinicopathological markers in BC (Table [3](#Tab3){ref-type="table"}). Supporting prior reports, PTEN protein loss by IHC and the PTEN abrogated state (either PTEN IHC-negative or *PTEN*-mutated) was significantly more common in ER-negative tumors (*P* = 0.0007 and *P* = 0.0013, respectively) and PgR-negative tumors (*P* = 0.0003 and *P* = 0.0007). PTEN loss or abrogation was also significantly correlated to higher grade (*P* = 0.0017 and *P* = 0.0012, respectively) and larger tumor size (*P* = 0.0018 and *P* = 0.0005). Similarly, EGFR overexpression was associated to hormone receptor negativity (*P* \< 0.0001) and increasing tumor grade (*P* = 0.0008), but not tumor size (*P* = 0.2160). Seventy-six % of *PIK3CA* mutants were ER-positive, and although larger studies have found an association between *PIK3CA* mutation and ER status \[[@CR2], [@CR6]\], this was not a significant enrichment in the present cohort perhaps as a consequence of limited sample size. Interestingly, *PIK3CA* mutations correlated with lower tumor grade (*P* = 0.0265) and lower S-phase fraction (*P* = 0.0416) (Table [3](#Tab3){ref-type="table"}). This result was supported also by reduced Ki67 (*P* = 0.0121). Using the 5-biomarker 'pathway hit' variable, 97 % (33/34) of ER-negative tumors had one or more pathway alterations compared to 65 % of ER-positive tumors (*P* = 0.0004; Table [3](#Tab3){ref-type="table"}). Similarly, 88 % of PgR-negative tumors had one or more pathway alterations compared to 67 % of PgR-positives (*P* = 0.0144; Table [3](#Tab3){ref-type="table"}).Table 3Correlation of PI3K Pathway Lesions to Other Clinicopathological MarkersER+ER--*nP*PgR+PgR --*nP*p53 mutp53 wt*nP*CK5/14 +CK5/14 --*nP*Grade 1Grade 2Grade 3*nP*\<20 mm20--49 mm50 mm+*nP*Node+Node --*nP*S--phase ≤6 %S--phase 6-10 %S--phase ≥10 %*nP*Basal-likeHER2Normal-likeLumALumB*nP*PTEN IHC--1114107**0.0007**817107**0.0003**159106**0.006**1113106**\<0.0001**0223106**0.002**3148107**0.002**148970.3924113850.06211220286**0.0003**PTEN IHC+6517592326567758274628477403524152811683113PTEN mut221120.334221120.600311120.115221050.0610041110.1660311110.175221010.855102910.7083000094**0.048**PTEN wt78306840396915868316835581453443016422010103417PTEN abrogated1214107**0.001**917107**0.0007**169106**0.003**1114106**\<0.0001**0224106**0.0012**3149107**0.0005**158970.2915113850.13512220286**\<0.0001**PTEN normal6417582325567748274528476393523152810683113HER2+13101130.09213101130.54813101120.0583181080.74017151120.80671331130.9791381030.4373310900.1773732392**0.0003**HER2--672357333158157272458285012433926143419383113EGFR+423112**\<0.0001**522112**\<0.0001**198111**\<0.0001**1511109**\<0.0001**0225111**0.0008**61651120.2161391020.5835314890.11216310091**\<0.0001**EGFR--74116322246047982947284710423825132976103216PIK3CA mut2271160.4802181160.15311181150.9664221090.75341014115**0.027**101631150.56816111050.474133993**0.042**535123950.446PIK3CA wt602750373353156842261264812403818143618762214INPP4B low101094**0.012**128940.7731010930.292613880.0573314940.954875930.928910850.750563730.23511117094**0.003**INPP4B high5816472727469605244519477343220930129102617Any PTEN/PI3K/INPP4B4417950.4343724950.3332436940.3051147890.4672134594**0.004**18348940.5612727840.37920626780.5941446189830.892None PTEN/PI3K/INPP4B2772410102442751316821518126812625127Any PTEN/PI3K/INPP4B/EGFR/HER24733106**0.0004**4337106**0.014**4039105**0.0004**1956101**0.0044**617561050.0812147121060.2684033960.559231030840.3192310916892**\<0.0001**None PTEN/PI3K/INPP4B/EGFR/HER225121532302621212915211124611002168Footnote: Definitions are as in Table [2](#Tab2){ref-type="table"}

*TP53* mutation was significantly positively correlated to PTEN/PI3K pathway alterations when analyzed as the combined pathway hit variable (*P* = 0.0004), and individually to PTEN alterations (*P* = 0.0029) and EGFR overexpression (*P* = 0.0001), but not to *HER2*-amplification, *PIK3CA* mutations, or *INPP4B* loss (*P* = 0.0576, *P* = 0.9663, and *P* = 0.2921, respectively) (Table [3](#Tab3){ref-type="table"}). Of note, 3 of 4 *PTEN* mutants were also *TP53* mutated. Consistent with the literature (see \[[@CR33]\] for a review), *TP53* mutations were significantly more common in ER-negative tumors compared to ER-positive tumors (62 % vs. 28 %, *P* = 0.0008); were prevalent in CK5/14^+^ basal-like tumors (61 %; *P* = 0.0341); and the mutational rate increased with grade (0 % mutated in grade 1, 28 % in grade 2, 47 % mutated in grade 3; *P* = 0.0031). No significant associations to patient outcome were found for the tumor group clusters, nor when testing individual or aggregated pathway lesions. This is likely due to the fact that there was a high rate of loss to follow-up (median follow-up 2.5 years, range 0 to 12 years).

Importantly, we found loss of PTEN to be common among IHC-BLBC (61 % vs. 16 % in non-BLBC; *P* \< 0.0001; Table [3](#Tab3){ref-type="table"}). Moreover, as expected EGFR overexpression was also significantly associated to the IHC-BLBC subtype (79 % vs. 12 %; *P* \< 0.0001). When utilizing the combined pathway hit variable, all IHC-BLBC (100 %) and all GEX-BLBC tumors (100 %) had ≥1 PTEN/PI3K pathway-activating lesion compared to 68 % and 62 % of non-basal-likes (*P* = 0.0044 and *P* = 0.0005).

The significant association between PTEN protein loss and BLBC status was confirmed in the independent series of consecutive breast cancer cases from the Netherlands Cancer Institute (NKI). Corroborating our findings in the Columbia cohort, CK5/14 was a good surrogate for BLBC status in the NKI series with 22 of 25 (88 %) CK5/14-positive cases belonging to the GEX-BLBC subtype (*P* \< 0.0001, *n* = 220). Furthermore, PTEN protein loss occurred significantly more often within the BLBC subtype whether defined by microarray subtyping (23/46; 50 % of GEX-BLBC had PTEN-loss; *P* = 0.0003, *n* = 245) or when defined by CK5/14-positivity (15/25; 60 % of IHC-BLBC had PTEN-loss; *P* \< 0.0001, *n* = 218). To note, stathmin protein levels were again significantly higher in tumors with PTEN protein loss (*P* = 0.0019, *n* = 237) and in tumors expressing the PTEN-loss gene expression signature (*P* \< 0.0001, *n* = 239).

Combined inhibition of PI3K and EGFR synergistically inhibits BLBC cell growth in vitro {#Sec17}
---------------------------------------------------------------------------------------

Based on these results, we hypothesized that monotherapy against either the PI3K or EGFR pathway nodes in BLBC may be ineffective due to resistance mediated by the alternative uninhibited signaling route, and therefore combination therapy could synergistically overcome this resistance mechanism. We first tested this in vitro using HCC70 BC cells, a relevant model which has high EGFR expression, *PTEN* mutation, and displays the BLBC phenotype by gene expression profiling \[[@CR30]\]. When cells were treated from 0.5 μM to 10 μM concentration, the small molecule EGFR inhibitor gefitinib was marginally growth inhibiting at low concentrations and cytostatic at high concentrations (Additional file [1](#MOESM1){ref-type="media"}: Figure S1a). However, when combined with 5 μM or 10 μM of the PI3K pathway inhibitor LY294002, dose-dependent synergistic growth inhibition was seen with a combination index of \<0.4 at all dose combinations (Fig. [2a-b](#Fig2){ref-type="fig"}). The effect of the combination treatment was accompanied by a marked induction of apoptosis (Fig. [2c](#Fig2){ref-type="fig"}). Similar synergistic effects for gefitinib plus LY294002 were seen in a second BLBC model cell line, SUM149, which also overexpresses EGFR and is mutant for *PTEN* (Fig. [2c-d](#Fig2){ref-type="fig"}; Additional file [1](#MOESM1){ref-type="media"}: Figure S1b).Fig. 2Combined inhibition of PI3K and EGFR synergistically inhibits BLBC cell growth via induction of apoptosis. The growth of the basal-like HCC70 (**a**) or SUM149 (**d**) cells was assessed after 4 days of treatment with single agent or combination treatment with LY294002 and gefitinib at the indicated concentrations. The results are shown as luminescence of viable cells. **b** Combination index plot for 5 or 10 μM LY294002 combined with 0.5, 1, 2, 4, 8, or 10 μM gefitinib (HCC70) or 0.5, 1, 2, 4 μM gefitinib (SUM149). **c** Dose-dependent induction of apoptosis in HCC70 cells by gefitinib and LY294002

Combined inhibition of PI3K and EGFR effectively suppresses PTEN-deficient and EGFR-overexpressing BLBC tumor growth in vivo {#Sec18}
----------------------------------------------------------------------------------------------------------------------------

The synergistic anti-proliferative and apoptotic effects of the combination of PI3K pathway and EGFR inhibitors in vitro suggest that targeting both PI3K and EGFR pathways may be a rational strategy for the treatment of BLBC. To explore the feasibility of this therapeutic strategy, we tested the safety and efficacy of inhibiting PI3K and EGFR in vivo using a mouse xenograft model with the BLBC cell line MDA-MB-468 which has DNA amplification and overexpression of EGFR as well as PTEN loss \[[@CR18], [@CR30], [@CR43]\]. Similar to the findings observed in HCC70 and SUM149 BCLB cells (Fig. [2](#Fig2){ref-type="fig"} and Additional file [1](#MOESM1){ref-type="media"}: Figure S1), we have previously shown that MDA-MB-468 cells also respond poorly to inhibition with LY294002 or gefitinib alone but are very sensitive to combination of these PI3K and EGFR inhibitors for a synergistic induction of apoptosis \[[@CR18]\]. Here, we utilized the PI3K-inhibitor, pegylated-17-hydroxywortmannin (PWT-458), which is completely miscible in feed water and relatively stable in plasma \[[@CR44]\]. Similar to our in vitro results, administration of PWT-458 or gefitinib alone slowed growth of tumors, but they still grew significantly (Fig. [3a](#Fig3){ref-type="fig"}). In contrast, treatment with both drugs profoundly suppressed the growth of the tumor xenografts and caused tumor regression. In addition, chronic administration of both PWT-458 at 100 mg/kg and gefitinib at 150 mg/kg for 5 consecutive days each week for 3 weeks was well tolerated with no weight loss in the animals (Additional file [2](#MOESM2){ref-type="media"}: Figure S2). Analysis of xenograft tumors by western blot indicated that gefitinib markedly inhibited EGFR phosphorylation but had no effect on AKT phosphorylation (Fig. [3b](#Fig3){ref-type="fig"}). By contrast, PWT-458 effectively caused reduction in AKT phosphorylation but had no effect on EGFR phosphorylation. However, gefitinib in combination with PWT-458 was associated with a profound decrease in the phosphorylation levels of both EGFR and AKT (Fig. [3b](#Fig3){ref-type="fig"}). These data highlight the effectiveness of concomitant inhibition of PI3K and EGFR in BLBC.Fig. 3Combination of PI3K and EGFR inhibitors markedly suppresses PTEN-deficient and EGFR-overexpressing BLBC tumor growth in vivo. **a** Mice with established MDA-MB-468 xenograft tumors were treated with PWT-458 (100 mg/kg 5 times/week), gefitinib (150 mg/kg five times/week), combination of both drugs, or vehicle control, and tumor size was measured by caliper two times per week. The results are presented as the mean tumor volume ± S.E.M. (*n* = 5 mice/group). **b** Representative tumors from mice in (**a**) were lysed 5 h after the final treatment with the indicated drugs. Tumor lysates were subjected to Western blot analysis for the indicated proteins

Discussion {#Sec19}
==========

We show in this study that PTEN/PI3K pathway alterations occur in more than half of an unselected population of 116 human breast carcinomas. Specifically, nearly all ER-negative breast tumors have one or more PTEN/PI3K pathway alterations in stark contrast to the rate in ER-positives. This result may have important clinical implications, as, with the exception of trastuzumab (Herceptin) for *HER2*-amplified BC, there are presently no targeted therapeutic options for patients with ER-negative disease. Our results suggest that therapies that specifically attack the PI3K pathway could be effective in this subtype of BC.

In addition to the previously reported high rate of *TP53* mutations among *HER2*-amplified \[[@CR33]\] and EGFR-overexpressing \[[@CR45]\] BC, we found *TP53* mutations to be significantly associated to PTEN abrogation. This is highly relevant in the context of recent work which demonstrated in human cells that oncogenic PI3K pathway activation via targeted *PTEN* disruption or *PIK3CA* mutation resulted in stabilization of p53 levels and induction of p53-mediated cellular senescence \[[@CR46]\]. It was concluded from this in vitro data that loss of *PTEN* or mutation of *PIK3CA* could elicit selective pressure on tumors to inactivate *TP53* \[[@CR46]\]. Our result supports this hypothesis in human breast tumors with respect to PTEN and p53, and further corroborates the cooperative nature between PTEN lesions and p53 inactivation that has also been observed in mouse models \[[@CR47]\]. Moreover, our results are consistent with the models proposed relating the p53 stress response pathway to the PTEN/PI3K growth pathway \[[@CR48]\]. Of 25 BCs with abrogation of PTEN and with *TP53* mutational data, we found 16 cases (64 %) with coincident mutation of *TP53*, including 3 cases with deleterious mutations to both genes. Therefore, our results demonstrate that the PTEN and p53 tumor suppressors are frequently inactivated in the same individual breast tumors.

Interestingly, *PIK3CA* mutations were significantly associated with lower tumor grade, lower S-phase fraction, and reduced Ki67 staining. This may indicate that, in vivo, *PIK3CA* mutation is a less potent driver of cell proliferation than, for example, PTEN alteration. The association of *PIK3CA* mutations to markers of favorable prognosis and to good outcome are consistent with other recent reports \[[@CR49]--[@CR51]\]. We previously reported that *PIK3CA* mutations were positively associated to ER, lymph node status, and *HER2* status \[[@CR2]\]. Our present study finds similar trends, however the associations were not significant may be due to the fact that the present study analyzed fewer cases compared to our prior report. We found reduced expression of *INPP4B* in ER-negative breast tumors as well as occurring most frequently in BLBC, consistent with prior reports \[[@CR6], [@CR9], [@CR10]\].

All cases in our identified cluster A had one or more PTEN/PI3K pathway activating lesions, and this cluster closely corresponds to the basal-like subtype of BC as defined by either CK5/14 positive staining or by GEX-based intrinsic molecular subtyping. Our tumor marker profiling informed a therapeutic strategy for co-targeting the EGFR and PTEN/PI3K nodes. This hypothesis was tested in vitro and in vivo and we show that cluster A-type BLBC tumors are sensitive to the combination therapy with the EGFR and PTEN/PI3K pathway inhibitors. Moreover, our data suggests that it could be clinically feasible to identify such patients using IHC panels or by gene expression profiling. It is interesting how PTEN/PI3K pathway lesions and our identified tumor clusters may relate to the other molecular subtypes. For example, our cluster C2/C3 corresponded most closely to the luminal A subtype, with prominent hormone receptor expression, a low *TP53* mutation rate, and reduced proliferation. The C2 cluster also contained no *PIK3CA* mutants, thus one would hypothesize that cases with this profile would respond best to selective ER modulators such as tamoxifen or to aromatase inhibitors \[[@CR52]--[@CR54]\]. Our clusters B and C4 correspond closely to the HER2 subtype, and most of these tumors have intact PTEN and are *PIK3CA* wild-type, making them ideal for traztuzumab-containing regimens \[[@CR15], [@CR17]\]. Subcluster C5 is ER^+^ with *TP53* mutation and has an overlap with the luminal B class. Given that PI3K pathway activation has been implicated in tamoxifen resistance \[[@CR52]--[@CR54]\] and *TP53* mutations in resistance to polychemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil \[[@CR55]\], we would hypothesize that tumors with a pathway profile like cluster C5 may require more intensive regimens than standard treatment. These hypotheses require further evaluation in appropriate models and patient material.

We found that BLBC tumors frequently have coincident EGFR-overexpression and loss of PTEN, which may implicate their selective advantage for maintaining BLBC transformation and contributing to the aggressive BLBC characteristics. We have previously found that in MDA-MB-468 BLBC cells with coexistent EGFR-overexpression and PTEN loss, inhibition of EGFR with gefitinib has no effect on PI3K/AKT signaling but effectively suppresses MAPK signaling \[[@CR18]\]. Thus, PTEN-deficient MDA-MB-468 cells proliferate and survive in an EGFR-independent manner. However, restoration of PTEN or inhibition of PI3K with LY294002 causes these cells to depend on EGFR/MAPK signaling pathway for survival, whereas combined inhibition of both PI3K/AKT and EGFR/MAPK signaling pathways synergistically induces apoptosis. Mechanistically, we have identified the BAD protein as a switch that integrates the antiapoptotic effects of the PI3K/AKT and EGFR/MAPK pathways \[[@CR18]\]. Each pathway is responsible for phosphorylation of BAD at a distinct site. Genetic induction of PTEN expression in combination of with the EGFR inhibitor gefitinib synergistically suppresses PTEN-deficient and EGFR-overexpressing BLBC tumor growth and causes tumor regression \[[@CR18]\]. The current study demonstrates effective synergy in vitro and in vivo using combination of pharmacological inhibitors targeting both EGFR and PI3K for the treatment of BLBC with concurrent PTEN loss and EGFR overexpression. We cannot rule out that off-target effects of LY294002 may have contributed to the synergistic effects observed when combined with gefitinib. Moreover, PMT-458 is a pan-PI3K inhibitor. To further delineate the signaling, these studies can be improved upon by the use of more specific inhibitors. Nevertheless, together our studies provide a heuristic model for understanding pathway interactions and suggest that combination therapy with EGFR/MAPK and PI3K/AKT pathway inhibitors is a rational strategy for BLBC treatment and deserves further pre-clinical/clinical testing. Our results parallel the situation seen in glioblastoma multiforme in which overexpression or amplification of EGFR and its variant, EGFRvIII, is commonly associated with *PTEN* deletion or mutation. This suggests that the coexistence of EGFR activation with PTEN loss may be a common paradigm in cancer that could potentially be exploited. This hypothesis should be extended beyond breast and brain cancers. For example, EGFR and PTEN appear to be involved in the pathogenesis of lung adenocarcinoma, however the prevalence of both lesions is not well studied. If loss of PTEN is frequent among EGFR-positive cancer, then this may be a contributing factor to the significant resistance to EGFR inhibitors seen in the clinic \[[@CR16]\] and further stresses the potential importance of combination therapies against both EGFR/MAPK and PTEN/PI3K/AKT signaling pathways. Interestingly, inhibition of AKT signaling appears to activate some RTKs via de-repression of RTK expression and increased RTK phosphorylation, including that for EGFR in some tumor models \[[@CR56]\]. Together, our data suggest that a promising strategy may be to co-target RTKs such as EGFR when targeting the PI3K/AKT pathway, and vice versa.

In summary, we have revealed novel relationships between PTEN/PI3K pathway lesions and of these lesions to the BC subtypes. Furthermore, we show that aberrant PTEN/PI3K signaling is closely correlated to mutation of *TP53*. Our biomarker and therapy results have important and obvious clinical implications for stratifying patients and designing clinical trials that target the PTEN/PI3K pathway as well as the EGFR/HER2 receptors and MAPK pathway. Finally, the fact that the majority of BCs have oncogenic PTEN/PI3K pathway lesions associated with the worst prognosis highlights the enormous need and potential benefit for targeting this pathway using recently developed PI3K and AKT inhibitors.

Conclusions {#Sec20}
===========

We have performed a comprehensive molecular characterization of unselected breast cancers and show a high rate of PTEN/PI3K pathway-related alterations in ER-negative breast cancer, an in particular show that basal-like breast cancers often display concomitant overexpression of EGFR and loss PTEN, the negative regulator of PI3K. We evaluated a combination therapy co-targeting EGFR and PI3K in models of basal-like breast cancer in vitro and demonstrate synergistic anti-cancer effects that shrinks tumors in vivo, with greater efficacy than either monotherapy. Our results support the clinical evaluation of combining EGFR/MAPK and PI3K/AKT pathway inhibitors for the treatment of BLBC.
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